DRMA Dermata Therapeutics, Inc.

Nasdaq dermatarx.com


$ 2.37 $ -0.10 (-3.98 %)    

Thursday, 20-Nov-2025 15:22:54 EST
QQQ $ 585.83 $ -25.72 (-4.2 %)
DIA $ 458.24 $ -8.44 (-1.81 %)
SPY $ 652.87 $ -20.04 (-2.98 %)
TLT $ 89.26 $ 0.27 (0.3 %)
GLD $ 374.74 $ -0.45 (-0.12 %)
$ 2.44
$ 2.51
$ 2.36 x 3
$ 2.45 x 212
$ 2.36 - $ 2.50
$ 2.39 - $ 23.70
158,770
na
2.5M
$ -17.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-17-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 03-21-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 02-21-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-28-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 09-27-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 dermata-therapeutics-q3-eps-165-misses-159-estimate

Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate o...

Core News & Articles

- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to to...

 dermata-therapeutics-to-present-phase-3-star-1-xyngari-abstract-highlighting-data-in-moderate-to-severe-acne-at-eadv-congress-2025

- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of...

Core News & Articles

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in...

 maxim-group-maintains-buy-on-dermata-therapeutics-lowers-price-target-to-10

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target fro...

 australian-patent-office-dermata-therapeutics-patent-application-for-dmt410-program-for-hyperhidrosis-titled-compositions-for-the-treatment-of-skin-conditions-australian-patent-no-2109284621

- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum tox...

 maxim-group-maintains-buy-on-dermata-therapeutics-lowers-price-target-to-3

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target fro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION